hsa-mir-1271: Hsa-mir-1271 is a microRNA that has been identified in various studies and is associated with different biological processes and diseases [PMC3281076]. It has been found to be unique to the platelet-micro-vesicle combined fraction and is not present in the platelet-derived fraction [PMC3281076]. Hsa-mir-1271 has also been shown to target ATGs16L, a gene involved in autophagy and implicated in inflammatory bowel disease susceptibility [PMC3281076]. In addition, hsa-mir-1271 has been linked to cancer cell resistance to cisplatin treatment [PMC8206191]. Silencing the expression of hsa-mir-1271 has been found to increase the level of CASP9, a gene involved in apoptosis, suggesting that hsa-mir-1271 may play a role in cell survival mechanisms [PMC8206191]. The expression of hsa-mir-1271 has also been shown to be altered in endometrial cell culture exposed to salinomycin, with increased expression observed at 12 and 48 hours but decreased expression at 24 hours [PMC8206191]. Hsa-mir-1271 has been identified as a potential diagnostic biomarker for malignant pleural mesothelioma (MPM) due to its association with carcinogenesis mechanisms and its upregulation in MPM compared to healthy controls [PMC4464514]. It is suggested that hsa-mir-1271, along with other miRNAs such as hsa-miR-96-5p and hsa-miR-409, may play a role in tumorigenesis and could serve as potential circulating biomarkers for MPM [PMC4464514].